ASGCL: Adaptive Sparse Mapping-based graph contrastive learning network for cancer drug response prediction
PLOS Computational Biology · 2025
DOI: 10.1371/journal.pcbi.1012748 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, 2025. Verfasst von Yunyun Dong und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Software, Taiyuan University of Technology, Taiyuan, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Machine Learning. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanxi Province Key Research and Development Program, Shanxi Province Applied Basic Research Program.
Abstract (Originalsprache)
Personalized cancer drug treatment is emerging as a frontier issue in modern medical research. Considering the genomic differences among cancer patients, determining the most effective drug treatment plan is a complex and crucial task. In response to these challenges, this study introduces the Adaptive Sparse Graph Contrastive Learning Network (ASGCL), an innovative approach to unraveling latent interactions in the complex context of cancer cell lines and drugs. The core of ASGCL is the GraphMorpher module, an innovative component that enhances the input graph structure via strategic node attribute masking and topological pruning. By contrasting the augmented graph with the original input, the model delineates distinct positive and negative sample sets at both node and graph levels. This dual-level contrastive approach significantly amplifies the model’s discriminatory prowess in identifying nuanced drug responses. Leveraging a synergistic combination of supervised and contrastive loss, ASGCL accomplishes end-to-end learning of feature representations, substantially outperforming existing methodologies. Comprehensive ablation studies underscore the efficacy of each component, corroborating the model’s robustness. Experimental evaluations further illuminate ASGCL’s proficiency in predicting drug responses, offering a potent tool for guiding clinical decision-making in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Software, Taiyuan University of Technology, Taiyuan, China.
- Institute of Big Data Science and Industry, Shanxi University, Taiyuan, China.
- School of Computer and Information Technology, Shanxi University, Taiyuan, China.
ORCID-Profile: Yuhua Qian, Ziting Yang
Förderung
- National Natural Science Foundation of China
- Shanxi Province Key Research and Development Program
- Shanxi Province Applied Basic Research Program
- Taiyuan University of Technology Youth
- Key Research and Development Program of Shanxi Province
- Applied Basic Research Program of Shanxi Province
- University-level Youth Fund of Taiyuan University of Technology
Zitieren
APA
Dong, Y., Zhang, Y., Qian, Y., Zhao, Y., Yang, Z., & Feng, X. (2025). ASGCL: Adaptive Sparse Mapping-based graph contrastive learning network for cancer drug response prediction. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1012748
Vancouver
Dong Y, Zhang Y, Qian Y, Zhao Y, Yang Z, Feng X. ASGCL: Adaptive Sparse Mapping-based graph contrastive learning network for cancer drug response prediction. PLOS Computational Biology. 2025. doi:10.1371/journal.pcbi.1012748
BibTeX
@article{Dong2025,
author = {Dong, Yunyun and Zhang, Yuanrong and Qian, Yuhua and Zhao, Yiming and Yang, Ziting and Feng, Xiufang},
title = {ASGCL: Adaptive Sparse Mapping-based graph contrastive learning network for cancer drug response prediction},
journal = {PLOS Computational Biology},
year = {2025},
doi = {10.1371/journal.pcbi.1012748}
}
EUVIMED